ReviewFrontiers in medicine2025
Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) are chronic eosinophilic diseases with serious multisystem manifestations. Patients with HES or EGPA often fail to receive a timely diagnosis, and while these conditions are considered rare, frequent under-recognition indicates that their true prevalence likely exceeds current estimates. Increased primary care physician (PCP) awareness of these systemic eosinophilic conditions and the "red flags" that should trigger referral will help more patients receive timely diagnosis and care. Patients with HES or EGPA present with a heterogeneous range of symptoms and manifestations that can overlap with other conditions, making diagnosis challenging. PCPs should be aware that the following are red flags that warrant further investigation and trigger expert referral: blood eosinophil count ≥10% of total peripheral white blood cells or ≥1,000 cells/μL; persistent hypereosinophilia, noting that systemic corticosteroid treatment may variably impact the degree of eosinophilia; refractory asthma symptoms with the need for prolonged or recurrent systemic corticosteroid treatment; reports of decreasing efficacy to asthma therapy; extra-pulmonary findings in the setting of eosinophilia; multiorgan system involvement; and evolving or worsening signs and symptoms over periods of weeks to months or years. PCPs play a key role in the diagnosis and management of rare eosinophilic diseases. By being aware of HES and EGPA and their associated red flags, PCPs are well-placed to recognize these conditions early, trigger further investigations, and coordinate effective multidisciplinary care. This can help patients receive a more accurate diagnosis on time and faster access to treatment, which may ultimately improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.